Atrys Health, S.A. (BME:ATRY)

Market Cap	193.94M -7.4%
Revenue (ttm)	147.68M +57.8%
Net Income	-97.39M
EPS	-1.28
Shares Out	75.91M
PE Ratio	n/a
Forward PE	23.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,417
Open	2.625
Previous Close	2.530
Day's Range	2.550 - 2.635
52-Week Range	2.310 - 3.590
Beta	0.52
Analysts	Strong Buy
Price Target	4.83 (+89.04%)
Earnings Date	Sep 10, 2026

About Atrys Health

Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 763
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ATRY

Financial Performance

In 2025, Atrys Health's revenue was 141.01 million, an increase of 8.49% compared to the previous year's 129.98 million. Losses were -100.30 million, 215.7% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for ATRY stock is "Strong Buy." The 12-month stock price target is €4.83, which is an increase of 89.04% from the latest price.

Price Target

€4.83

(89.04% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 6, 2026

Data Sources Report a data error